CASE COMMENTS: CARTELS - EUROPEAN UNION - DEFERRED ENTRY AGREEMENT - FINES

Pay-for-delay: The European Commission fines two pharmaceutical companies €60.5 million for delaying the entry of a generic drug on the market (Teva et Cephalon)

KEYWORDS
Reference

Eur. comm., 26 Nov. 2020, Teva and Cephalon, IP/20/2220

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. On 26 November 2020 and following other similar cases (the cardiovascular drug perindopril, the antidepressant citalopram

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

This document is protected by copyright laws and international copyright treaties. Non-authorised use of this document constitutes a violation of the publisher's rights and may be punished by up to 3 years imprisonment and up to a € 300 000 fine (Art. L 335-2 Code de la Propriété Intellectuelle). Personal use of this document is authorised within the limits of Art. L 122-5 CPI and DRM protection.

PDF Version

Author

  • European Court of Justice (Luxembourg)
    France 57 contributions 22191 visits

Quotation

Ludovic Bernardeau, Pay-for-delay: The European Commission fines two pharmaceutical companies €60.5 million for delaying the entry of a generic drug on the market (Teva et Cephalon), 26 November 2020, Concurrences N° 1-2021, Art. N° 99116, p. 120

Visites 150

All reviews